Tilray Inc (NASDAQ:TLRY - Free Report) - Equities research analysts at Atb Cap Markets dropped their FY2028 EPS estimates for Tilray in a research report issued on Monday, December 16th. Atb Cap Markets analyst F. Gomes now expects that the company will post earnings per share of $0.01 for the year, down from their previous forecast of $0.06. The consensus estimate for Tilray's current full-year earnings is ($0.14) per share.
Tilray (NASDAQ:TLRY - Get Free Report) last released its quarterly earnings results on Thursday, October 10th. The company reported ($0.04) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.04). The business had revenue of $200.00 million for the quarter, compared to analysts' expectations of $218.70 million. Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The company's revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.10) EPS.
Separately, Roth Mkm dropped their target price on shares of Tilray from $2.00 to $1.75 and set a "neutral" rating for the company in a report on Friday, October 11th.
Read Our Latest Report on TLRY
Tilray Price Performance
Shares of TLRY stock traded down $0.08 during mid-day trading on Wednesday, reaching $1.16. The stock had a trading volume of 27,448,055 shares, compared to its average volume of 25,842,883. The company has a market cap of $1.05 billion, a P/E ratio of -4.30 and a beta of 2.08. The company has a current ratio of 2.47, a quick ratio of 1.57 and a debt-to-equity ratio of 0.08. Tilray has a 12-month low of $1.15 and a 12-month high of $2.97. The business has a 50-day simple moving average of $1.46 and a 200 day simple moving average of $1.66.
Insider Activity at Tilray
In other news, CFO Carl A. Merton bought 26,000 shares of the firm's stock in a transaction that occurred on Friday, November 15th. The shares were purchased at an average price of $1.36 per share, for a total transaction of $35,360.00. Following the completion of the transaction, the chief financial officer now owns 26,000 shares in the company, valued at $35,360. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.87% of the company's stock.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. Synovus Financial Corp boosted its stake in Tilray by 176.7% in the 3rd quarter. Synovus Financial Corp now owns 36,092 shares of the company's stock worth $64,000 after buying an additional 23,046 shares during the last quarter. Barclays PLC lifted its holdings in shares of Tilray by 600.4% during the 3rd quarter. Barclays PLC now owns 204,144 shares of the company's stock worth $359,000 after acquiring an additional 174,997 shares during the period. Toronto Dominion Bank boosted its position in shares of Tilray by 454.5% in the third quarter. Toronto Dominion Bank now owns 128,923 shares of the company's stock worth $227,000 after acquiring an additional 105,671 shares during the last quarter. XTX Topco Ltd boosted its position in shares of Tilray by 1,079.7% in the third quarter. XTX Topco Ltd now owns 281,504 shares of the company's stock worth $495,000 after acquiring an additional 257,641 shares during the last quarter. Finally, State Street Corp grew its holdings in Tilray by 4.7% in the third quarter. State Street Corp now owns 1,961,338 shares of the company's stock valued at $3,452,000 after purchasing an additional 88,079 shares during the period. Hedge funds and other institutional investors own 9.35% of the company's stock.
About Tilray
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Further Reading
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
